PLoS ONE (Jan 2015)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.

  • Gautam Borthakur,
  • Seshagiri Duvvuri,
  • Vivian Ruvolo,
  • Durga Nand Tripathi,
  • Sujan Piya,
  • Jared Burks,
  • Rodrigo Jacamo,
  • Kensuke Kojima,
  • Peter Ruvolo,
  • Juan Fueyo-Margareto,
  • Marina Konopleva,
  • Michael Andreeff

DOI
https://doi.org/10.1371/journal.pone.0139254
Journal volume & issue
Vol. 10, no. 10
p. e0139254

Abstract

Read online

MDM2 (mouse double minute 2) inhibitors that activate p53 and induce apoptosis in a non-genotoxic manner are in clinical development for treatment of leukemias. P53 can modulate other programmed cell death pathways including autophagy both transcriptionally and non-transcriptionally. We investigated autophagy induction in acute leukemia by Nutlin 3a, a first-in-class MDM2 inhibitor. Nutlin 3a induced autophagy in a p53 dependent manner and transcriptional activation of AMP kinase (AMPK) is critical, as this effect is abrogated in AMPK -/- mouse embryonic fibroblasts. Nutlin 3a induced autophagy appears to be pro-apoptotic as pharmacological (bafilomycin) or genetic inhibition (BECLIN1 knockdown) of autophagy impairs apoptosis induced by Nutlin 3a.